Search

Pop-up stores are considered an alternative or a further development of the pioneering flagship store concept. They describe a temporary store concept that displays products in an unexpected way to attract the consumers’ attention (Hutter 2013). So far, this store format has mainly been applied to the USA and the UK, and has been insufficiently studied. This paper summarizes interim results of a pilot study on pop-up stores, which focuses on identifying factors for their success. Pop-up Stores stellen eine konzeptionelle Weiterentwicklung von Flagship Stores dar. Pop-Up Stores beschreiben ein zeitlich limitiertes Storekonzept, bei dem Produkte in einer ungewöhnlichen und finanziell erschwinglichen Art und Weise dem Kunden präsentiert werden (Hutter 2013). Bislang wird dieses neuartige Storekonzept überwiegend in den USA und in UK praktiziert und wissenschaftlich diskutiert. Der vorliegende Beitrag fasst erste Zwischenergebnisse einer Pilotstudie zu den Erfolgsfaktoren von Pop-up Stores zusammen.

Background Continuing medical education (CME) seeks to improve patient health by promoting clinician practice change. Many patients with a diagnosis of either bipolar disorder or schizophrenia are predisposed to cardiovascular risk, and the use of second-generation antipsychotic (SGA) medications that can cause significant weight gain and altering of lipid profiles may compound this risk. An educational analysis identified a performance gap related to psychiatrists' gathering of baseline lipid data in their patients. Objective This study analyzes the degree to which participation in 2 CME activities improves clinicians' rates of lipid monitoring in patients with mental illness who take SGAs. Study Design After participation in 1 or 2 CME activities on improved cardiometabolic monitoring in patients with major mental illness—in which one activity focused on schizophrenia and the other on bipolar disorder—a nationwide group (NG) of clinician learners was surveyed about lipid monitoring practices among patients during these patients' first 16 weeks of SGA therapy over a 12-month period. Responses from the NG were compared with those from 1) a nationwide control group (CG) and 2) a local group of activity participants at the Lindner Center of HOPE—Cincinnati, Ohio (LG), whose measured rates were documented via medical records data extraction; the LG also received institutional encouragement and support for practice change for lipid monitoring in these patients. Results Percentages of patients monitored by clinicians in the NG increased by 18.0 percentage points over 1 year from baseline ( P = 0.00001) and represented a rate change that was higher than that seen in the CG ( P Conclusions CME interventions can improve lipid-monitoring practices among clinicians who treat patients with major mental illness who take SGAs. Local, institutional support for guideline-recommended monitoring may increase nationwide CME-induced change yet further.

Mood disorders are among the most common neuropsychiatric disorders. Major depressive disorder and bipolar disorder affect 14.8 million (6.7%) and 5.7 million (2.6%) adults in the United States aged 18 years and over in a given year, respectively; and these may be conservative estimates. In addition, these disorders are associated with significant disability and morbidity for the patient, and enormous societal costs. Regrettably, mortality is too common for patients affected; more than 90% of people who commit suicide have a diagnosable mental disorder, most commonly a depressive disorder. The 3rd Annual Chair Summit, The Master Class for Neuroscience Professional Development, held in Chicago, Illinois (August 2010), a comprehensive continuing medical education (CME) conference on neuroscience targeted to psychiatry and neurology clinicians and featuring relevant department chairs as faculty, included numerous educational sessions on unipolar and bipolar mood disorders. Notable topics in depression were management of subtypes (psychotic and anxious), onset in late life, available evidence regarding use of complementary and alternative medicine, and the impact of depression treatment on cardiovascular disease. Bipolar disorder sessions focused on patients with childhood onset of illness and those who require systematic therapy trials in order to arrive at the optimal, individualized treatment plan. Additionally, a forward-looking session was held on innovations, both diagnostic and therapeutic, on the horizon for improving care of bipolar disorder. This 2nd article of 5 in a CME-certified companion series presents highlights of these sessions with summary points connecting research to clinical practice for each topic.

The Institute of Medicine report entitled Redesigning Continuing Education in the Health Professions (2010) calls for continuing medical education (CME) to align learning with health professionals’ needs. To meet that goal, The 3rd Annual Chair Summit, The Master Class for Neuroscience Professional Development, held in Chicago, Illinois (August 2010), brought together chairpersons in psychiatry and neurology to act as expert peer teachers for frontline, clinician learners. Faculty and learners collaboratively evaluated evidence, shared ideas and clinical practice challenges, developed individualized clinical strategies, explored the role of the multidisciplinary team, discussed health-system issues, and translated the neuroscience discoveries into patient-centered practice improvements. This 5th and final article in the companion series, “Meeting Highlights of the 3rd Annual Chair Summit, The Master Class for Neuroscience Professional Development, 2010” will summarize psychiatric perspectives on neurological illnesses and injuries: multiple sclerosis; traumatic brain injury; sleep-wake disorders, including obstructive sleep apnea; Alzheimer’s disease management; and psychiatric care of older persons, including a case from one chart review session. Highlights of current and emerging developments related to psychiatric treatment perspectives for the management of neurological illness are discussed. Summary points connecting research to clinical practice for each topic are also presented.

Health care providers encounter many patients who have a typical, bread-and-butter symptom presentation and illness course, and for whom developing a treatment plan is relatively straightforward. However, some patients have cases that are challenging because 1) their illnesses are atypical, severe, or treatment-refractory in nature; 2) their conditions are less frequently encountered in the clinical setting; or 3) optimal treatment has not yet been well-studied and clearly defined. In the neurosciences, such challenges often seem to be the rule more than the exception. Continuing medical education (CME) can help clinicians address these challenges and promote clinical competence regarding innovations in neuroscience technologies. In August 2010, psychiatry and neurology health care providers participated in a comprehensive neuroscience CME conference—The 3rd Annual Chair Summit, The Master Class for Neuroscience Professional Development—that featured faculty chairpersons of psychiatry and neurology departments. This 4th article of 5 in a CME-certified companion series presents meeting highlights on managing the complexities of neuropsychiatric care and on scientific advances, especially technology-based innovations. Specifically, clinical topics focus on recognizing attention deficit hyperactivity disorder that persists into adulthood; differential diagnosis of rage and aggression; treating borderline personality disorder; preventing suicide; and implementing care strategies for physician addiction. Rounding out this attention to difficult cases, technology highlights pertained to advanced diagnostic innovations in functional magnetic resonance imaging and to brain stimulation treatment strategies (ie, electroconvulsive therapy, deep brain stimulation, repetitive transcranial magnetic stimulation, and vagus nerve stimulation). This article contains several patient cases and summary points connecting research to clinical practice.